Physician profile
Amee R Majmundar
NPI 1093794620
$11,595.80
in general payments reported to CMS, 2019-2025
29 companies · $6,651 in 2025
The $6,651 reported for 2025 was more than what 87% of Allergy & Immunology (Internal Medicine) providers received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $383 · 2020: $520 · 2021: $17.34 · 2022: $432 · 2023: $2,397 · 2024: $1,197 · 2025: $6,651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,585 · Food and Beverage: $4,028 · Travel and Lodging: $617 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,584.50 |
| Food and Beverage | $4,027.54 |
| Travel and Lodging | $616.69 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $3,500.06 | 2020-2025 | Andembry, Hizentra, Haegarda |
| Genzyme Corporation | $2,420.97 | 2019-2025 | |
| Genentech USA, INC. | $1,367.01 | 2022-2024 | Xolair |
| Astrazeneca Pharmaceuticals Lp | $1,056.20 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $973.09 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $342.82 | 2019-2025 | |
| Glaxosmithkline, LLC. | $316.84 | 2019-2025 | Nucala, Trelegy Ellipta |
| Amgen INC. | $298.49 | 2019-2024 | Tezspire, Prolia, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $221.84 | 2023-2025 | Cuvitru, Takhzyro |
| Biocryst US Sales Co., LLC | $157.60 | 2022-2025 | Orladeyo |
| Grifols USA, LLC | $116.98 | 2023-2024 | Xembify, Gamunex-C |
| Ars Pharmaceuticals Operations, INC. | $116.23 | 2025 | Neffy |
| Cranial Technologies, INC | $89.71 | 2020-2025 | Doc Band |
| Blueprint Medicines Corporation | $85.14 | 2024-2025 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.42 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $71.06 | 2019-2025 | |
| Novo Nordisk INC | $57.25 | 2020-2023 | Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.83 | 2019-2023 | Xifaxan |
| Alk-Abello, INC | $37.08 | 2020 | |
| Merck Sharp & Dohme LLC | $36.49 | 2023-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Teva Pharmaceuticals USA, INC. | $32.92 | 2020 | |
| Ionis Pharmaceuticals, INC. | $32.82 | 2025 | Dawnzera |
| Corcept Therapeutics | $29.37 | 2025 | Korlym |
| Exact Sciences Corporation | $24.89 | 2024 | Cologuard Collection Kit |
| Abbott Laboratories | $22.44 | 2023 | Freestyle Libre 3 |
| Optinose US, INC. | $19.62 | 2020 | |
| Bio Products Laboratory USA, INC. | $15.17 | 2019 | |
| Verona Pharma, INC. | $14.99 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $14.47 | 2023 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amee Majmundar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.